These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 31729964)

  • 1. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
    JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
    Fokas E; Schlenska-Lange A; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Kirste S; Jacobasch L; Allgäuer M; Flentje M; Germer CT; Grützmann R; Hildebrandt G; Schwarzbach M; Bechstein WO; Sülberg H; Friede T; Gaedcke J; Ghadimi M; Hofheinz RD; Rödel C;
    JAMA Oncol; 2022 Jan; 8(1):e215445. PubMed ID: 34792531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
    Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY
    BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
    Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
    Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
    BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
    Diefenhardt M; Fleischmann M; Martin D; Hofheinz RD; Piso P; Germer CT; Hambsch P; Grützmann R; Kirste S; Schlenska-Lange A; Ghadimi M; Rödel C; Fokas E;
    Radiother Oncol; 2023 Feb; 179():109455. PubMed ID: 36572280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.
    Fokas E; Allgäuer M; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Schmiegel W; Jacobasch L; Weitz J; Folprecht G; Schlenska-Lange A; Flentje M; Germer CT; Grützmann R; Schwarzbach M; Paolucci V; Bechstein WO; Friede T; Ghadimi M; Hofheinz RD; Rödel C;
    J Clin Oncol; 2019 Dec; 37(34):3212-3222. PubMed ID: 31150315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
    Margalit O; Mamtani R; Kopetz S; Yang YX; Lawrence YR; Abu-Gazala S; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Oncologist; 2019 Aug; 24(8):e671-e676. PubMed ID: 30696723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
    Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
    Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
    Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
    BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).
    Schrag D; Weiser M; Saltz L; Mamon H; Gollub M; Basch E; Venook A; Shi Q
    Clin Trials; 2019 Apr; 16(2):165-175. PubMed ID: 30688523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
    Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J
    JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.